A16Z outlines its rationale for leading Boltz's $110M Series A, a molecular design AI platform that offers frontier models on a consumption-based basis to pharma and biotech companies, with 50x growth in token usage in four months.
Topics: Biotech & Life Sciences · AI Infrastructure
Published by A16Z · their site ↗
SandHill indexes 800+ venture capital blogs and newsletters and sends the best of them every Sunday. Browse the sources · browse by topic · read the blog.
Suggest a blog or newsletter for the SandHill index. We track the RSS feed and feature the best pieces in the weekly digest.
The latest theses & analyses from 800+ venture investors, curated into one email. Join 5,000+ investors, founders and LPs.